Astellas Pharma Inc. (ALPMY)
OTCMKTS
· Delayed Price · Currency is USD
12.53
-0.04 (-0.32%)
Sep 12, 2024, 1:35 PM EDT
Astellas Pharma Revenue
Astellas Pharma had revenue of 473.12B JPY in the quarter ending June 30, 2024, with 26.17% growth. This brings the company's revenue in the last twelve months to 1.70T, up 12.57% year-over-year. In the fiscal year ending March 31, 2024, Astellas Pharma had annual revenue of 1.60T with 5.60% growth.
Revenue (ttm)
1,701.81B JPY
Revenue Growth
+12.57%
P/S Ratio
2.13
Revenue / Employee
115.35M JPY
Employees
14,754
Market Cap
22.54B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
Mar 31, 2020 | 1,300.84B | -5.51B | -0.42% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAstellas Pharma News
- 1 day ago - Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 - PRNewsWire
- 7 days ago - Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies - PRNewsWire
- 8 days ago - Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society - Benzinga
- 8 days ago - Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society - PRNewsWire
- 15 days ago - European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer - PRNewsWire
- 16 days ago - Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy - PRNewsWire
- 21 days ago - China confirms charges laid against Japanese citizen accused of spying - South China Morning Post
- 22 days ago - Japan's Astellas says employee indicted by China's prosecutors - Reuters